IDH1 and acute myeloid leukemia: In a randomized, double-blind, placebo-controlled phase III clinical trial, Ivosidenib extended the median overall survival of patients with relapsed/refractory IDH1-mutated AML from 4.3 months to 8.8 months and increased the objective response rate from 13 to 42% [14].